

September 2011-Addendum

The following changes to the Neighborhood formulary were recently approved by the Pharmacy and Therapeutics (P&T) Committee. These changes are effective immediately unless otherwise indicated.

Therapeutic Class/Drug Name	Strategy or Medications Added or Modified	Rationale
Victrelis™	Add Victrelis to the formulary with prior authorization.	Both Victrelis and Incivek are new options for the treatment of Chronic Hepatitis C Virus that offer a significant improvement in rate of sustained virologic response both in previously treated and treatment naïve patients. These agents must be used with a pegylated interferon and ribavirin. The new agents are expensive and each has it's their own specific treatment regimen. The other main difference is related to their side effect profile. Victrelis offers a cost advantage without compromising the rate of SVR
Incivek™	Incivek will be non-formulary but available to those members who are not candidates for Victrelis. Rationale will need to be provided for not using Victrelis.	

Please call the Pharmacy Help Desk at 1-401-459-6020 for pharmacy authorization requests or for further information on the Neighborhood formulary.

Explanation of Terms

Products listed as "added" are available to most Neighborhood members at zero copay, if restrictions apply they will be indicated on this form and in the electronic formulary. Drugs may be limited to certain age groups (an AGE EDIT), by demonstrating prior therapies have been attempted (a STEP EDIT), in quantity allowed per 30 days (a QUANTITY LIMIT), or by requiring precertification for use from NHPRI (a PRIOR AUTHORIZATION). Products listed as "removed" are no longer available to Neighborhood members and are considered non-formulary or benefit exclusions. Physicians may request these products via the medical necessity request process only.